Abstract
The development of ligands for the A3 adenosine receptor (AR) has been directed mainly by traditional medicinal chemistry, but the influence of structure-based approaches is increasing. Rhodopsin-based homology modeling had been used for many years to obtain three-dimensional models of the A3AR, and different A3AR models have been published describing the hypothetical interactions with known A3AR ligands having different chemical scaffolds. The recently published structure of the human A2AAR provides a new template for GPCR modeling, however even use of the A2AAR as a template for modeling other AR subtypes is still imprecise. The models compared here are based on bovine rhodopsin, the human β2-adrenergic receptor, and the A2AAR as templates. The sequence of the human A3AR contains only one cysteine residue (Cys166) in the second extracellular loop (EL2), which putatively forms a conserved disulfide bridge with the respective cysteine residues of TM3 (Cys83). Homology models of the A3AR have been helpful in providing structural hypotheses for the design of new ligands. Site-directed mutagenesis of the A3AR shows an important role in ligand recognition for specific residues in TM3, TM6 and TM7.
Current Pharmaceutical Design
Title: Human A3 Adenosine Receptor as Versatile G Protein-Coupled Receptor Example to Validate the Receptor Homology Modeling Technology
Volume: 15 Issue: 35
Author(s): Erika Morizzo, Stephanie Federico, Giampiero Spalluto and Stefano Moro
Affiliation:
Abstract: The development of ligands for the A3 adenosine receptor (AR) has been directed mainly by traditional medicinal chemistry, but the influence of structure-based approaches is increasing. Rhodopsin-based homology modeling had been used for many years to obtain three-dimensional models of the A3AR, and different A3AR models have been published describing the hypothetical interactions with known A3AR ligands having different chemical scaffolds. The recently published structure of the human A2AAR provides a new template for GPCR modeling, however even use of the A2AAR as a template for modeling other AR subtypes is still imprecise. The models compared here are based on bovine rhodopsin, the human β2-adrenergic receptor, and the A2AAR as templates. The sequence of the human A3AR contains only one cysteine residue (Cys166) in the second extracellular loop (EL2), which putatively forms a conserved disulfide bridge with the respective cysteine residues of TM3 (Cys83). Homology models of the A3AR have been helpful in providing structural hypotheses for the design of new ligands. Site-directed mutagenesis of the A3AR shows an important role in ligand recognition for specific residues in TM3, TM6 and TM7.
Export Options
About this article
Cite this article as:
Morizzo Erika, Federico Stephanie, Spalluto Giampiero and Moro Stefano, Human A3 Adenosine Receptor as Versatile G Protein-Coupled Receptor Example to Validate the Receptor Homology Modeling Technology, Current Pharmaceutical Design 2009; 15 (35) . https://dx.doi.org/10.2174/138161209789824777
DOI https://dx.doi.org/10.2174/138161209789824777 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
GABAA Receptors, Anesthetics and Anticonvulsants in Brain Development
CNS & Neurological Disorders - Drug Targets Mechanisms in the Bed Nucleus of the Stria Terminalis Involved in Control of Autonomic and Neuroendocrine Functions: A Review
Current Neuropharmacology Resting-State Networks in Schizophrenia
Current Topics in Medicinal Chemistry Tau in Alzheimer Disease and Related Tauopathies
Current Alzheimer Research The Interplay Between Depression and Parkinson´s Disease: Learning the Link Through Ca<sup>2+</sup>/cAMP Signaling
Current Protein & Peptide Science Multiple Roles of Histamine in Autoimmune Demyelinating Disease of the Central Nervous System
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Meet Our Editorial Board Member
Current Neuropharmacology Patent Selections
Recent Patents on Inflammation & Allergy Drug Discovery Stimulant-Related Psychosis in ADHD Treatment: An Update for Past 10 Years
Current Psychopharmacology Hippocampal Morphology and Autobiographic Memory in Mild Cognitive Impairment and Alzheimer’s Disease
Current Alzheimer Research Anticonvulsant and Neurotoxicity Evaluation of Some N4 Phenyl Substituted Pyridyl Semicarbazones
Central Nervous System Agents in Medicinal Chemistry <i>Moringa</i> oleifera Leaf Extract Attenuates Pb Acetate-induced Testicular Damage in Rats
Combinatorial Chemistry & High Throughput Screening Validated Microemulsion Liquid Chromatography-Fluorescence Method for the Quantification of Duloxetine and its Two Main Metabolites in Plasma: Application to Clinical Pharmacokinetic Studies
Current Pharmaceutical Analysis Delta Opioid Peptides Derived from Plant Proteins
Current Pharmaceutical Design Cell-Based Therapy to Promote Angiogenesis in the Brain Following Ischemic Damage
Current Vascular Pharmacology Neurogenic Inflammation and Asthma
Inflammation & Allergy - Drug Targets (Discontinued) Mitochondrial Uncoupler Proteins
Current Enzyme Inhibition Editorial: Zebrafish Psychopharmacology
Current Psychopharmacology Pharmacovigilance and the Cardiovascular System: Two Sides to Every Story
Current Drug Safety Regional Grey Matter Loss and Brain Disconnection Across Alzheimer Disease Evolution
Current Medicinal Chemistry